|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2000, Vol. 96, No. 5, pp. 1999-2001
BRIEF REPORT
Chimeric Fv- or Fv- receptors are not sufficient to
induce activation or cytokine production in peripheral T
cells
Thomas Brocker
From the Institute for Biology III, Department of
Molecular Immunology at the Max-Planck-Institute for Immunobiology, and
Basel Institute for Immunology, Basel, Switzerland.
In current clinical trials, chimeric antibody-like receptors
fused to signaling domains derived from TCR- or Fc( )RI -chain are tested for their ability to lyse tumor cells in vivo. In this study, the function of primary T cells expressing such receptors has
been investigated in transgenic mice. These receptors cannot induce
proliferation of resting T cells or trigger the production of optimal
amounts of cytokines. It is further demonstrated that an initial low
presence of cytokine message and protein is disappearing rather fast,
whereas the triggering of endogenous TCR/CD3 in the same cells leads to
normal prolonged cytokine production. The direct clinical relevance of
these findings is further underlined by the increased in vivo tumor
rejection by T cells expressing chimeric receptors in presence of
exogenous interleukin-2. Therefore, adoptive T-cell therapy using
primary T cells transfected with single chain receptors might benefit
substantially from the accompanying administration of cytokines.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord
T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
Clin. Cancer Res.,
November 1, 2009;
15(21):
6503 - 6510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J.N. Cooper
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells.
Cancer Res.,
November 15, 2006;
66(22):
10995 - 11004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P.F. Gade, W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. Brentjens, X.-S. Zhong, M. Stephan, J. Stefanski, et al.
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Cancer Res.,
October 1, 2005;
65(19):
9080 - 9088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Friedmann-Morvinski, A. Bendavid, T. Waks, D. Schindler, and Z. Eshhar
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation
Blood,
April 15, 2005;
105(8):
3087 - 3093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Finney, A. N. Akbar, and A. D. G. Lawson
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain
J. Immunol.,
January 1, 2004;
172(1):
104 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar
Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes
Cancer Res.,
May 15, 2003;
63(10):
2470 - 2476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy
Blood,
March 15, 2002;
99(6):
2009 - 2016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Geiger, P. Nguyen, D. Leitenberg, and R. A. Flavell
Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes
Blood,
October 15, 2001;
98(8):
2364 - 2371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
